Literature DB >> 18725320

The design, structures and therapeutic potential of protein epitope mimetics.

John A Robinson1, Steve Demarco, Frank Gombert, Kerstin Moehle, Daniel Obrecht.   

Abstract

Using a biologically relevant peptide or protein structure as a starting point for lead identification represents one of the most powerful approaches in modern drug discovery. Here, we focus on the protein epitope mimetic (PEM) approach, where folded 3D structures of peptides and proteins are taken as starting points for the design of synthetic molecules that mimic key epitopes involved in protein-protein and protein-nucleic acid interactions. By transferring the epitope from a recombinant to a synthetic scaffold that can be produced by parallel combinatorial methods, it is possible to optimize target affinity and specificity as well as other drug-like ADMET properties. The PEM technology is a powerful tool for target validation, and for the development of novel PEM-based drugs.

Mesh:

Substances:

Year:  2008        PMID: 18725320     DOI: 10.1016/j.drudis.2008.07.008

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  32 in total

1.  Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV.

Authors:  A McGregor; K Y Choi; M R Schleiss
Journal:  Virology       Date:  2010-11-20       Impact factor: 3.616

Review 2.  Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.

Authors:  M P Rettig; G Ansstas; J F DiPersio
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

3.  Protein-protein interactions: making drug design second nature.

Authors:  Dan L Sackett; David Sept
Journal:  Nat Chem       Date:  2009-11       Impact factor: 24.427

4.  Drug discovery: tools and rules for macrocycles.

Authors:  Christian Heinis
Journal:  Nat Chem Biol       Date:  2014-07-20       Impact factor: 15.040

5.  Design and Evolution of a Macrocyclic Peptide Inhibitor of the Sonic Hedgehog/Patched Interaction.

Authors:  Andrew E Owens; Ivan de Paola; William A Hansen; Yi-Wen Liu; Sagar D Khare; Rudi Fasan
Journal:  J Am Chem Soc       Date:  2017-08-30       Impact factor: 15.419

6.  Designer macrocyclic organo-peptide hybrids inhibit the interaction between p53 and HDM2/X by accommodating a functional α-helix.

Authors:  Jessica M Smith; John R Frost; Rudi Fasan
Journal:  Chem Commun (Camb)       Date:  2014-04-07       Impact factor: 6.222

7.  A Macrocyclic Peptide Ligand Binds the Oncogenic MicroRNA-21 Precursor and Suppresses Dicer Processing.

Authors:  Matthew D Shortridge; Matthew J Walker; Tom Pavelitz; Yu Chen; Wen Yang; Gabriele Varani
Journal:  ACS Chem Biol       Date:  2017-05-02       Impact factor: 5.100

8.  PEP-SiteFinder: a tool for the blind identification of peptide binding sites on protein surfaces.

Authors:  Adrien Saladin; Julien Rey; Pierre Thévenet; Martin Zacharias; Gautier Moroy; Pierre Tufféry
Journal:  Nucleic Acids Res       Date:  2014-05-06       Impact factor: 16.971

9.  Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.

Authors:  Giorgio Colombo; Barbara Margosio; Laura Ragona; Marco Neves; Silvia Bonifacio; Douglas S Annis; Matteo Stravalaci; Simona Tomaselli; Raffaella Giavazzi; Marco Rusnati; Marco Presta; Lucia Zetta; Deane F Mosher; Domenico Ribatti; Marco Gobbi; Giulia Taraboletti
Journal:  J Biol Chem       Date:  2010-01-07       Impact factor: 5.157

10.  Genetically-encoded discovery of proteolytically stable bicyclic inhibitors for morphogen NODAL.

Authors:  Jeffrey Y-K Wong; Raja Mukherjee; Jiayuan Miao; Olena Bilyk; Vivian Triana; Mark Miskolzie; Antoine Henninot; John J Dwyer; Serhii Kharchenko; Anna Iampolska; Dmitriy M Volochnyuk; Yu-Shan Lin; Lynne-Marie Postovit; Ratmir Derda
Journal:  Chem Sci       Date:  2021-06-17       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.